160 related articles for article (PubMed ID: 9327247)
21. Burkholderia cepacia septicemia in a pediatric oncology patient: a pharmacotherapy challenge.
Durham SH; Lee AE; Assanasen C
Ann Pharmacother; 2012 Jun; 46(6):e16. PubMed ID: 22570430
[TBL] [Abstract][Full Text] [Related]
22. Burkholderia cepacia endophthalmitis: clinico-microbiologic profile and outcomes.
Sachdeva V; Pathengay A; Joseph J; Sharma S; Das T
Retina; 2011 Oct; 31(9):1801-5. PubMed ID: 21478807
[TBL] [Abstract][Full Text] [Related]
23. In vitro activity of azithromycin in combination with amikacin, ceftazidime, ciprofloxacin or imipenem against clinical isolates of Acinobacter baumannii.
Fernández-Cuenca F; Martínez-Martínez L; Pascual A; Perea EJ
Chemotherapy; 2003 May; 49(1-2):24-6. PubMed ID: 12714805
[TBL] [Abstract][Full Text] [Related]
24. Report - Prevalence of hospital acquired Burkholderia cepacia infection and its antimicrobial susceptibility in a Chinese hospital.
Duan J; Kang J; Han T; Ma Y; Guo Q; Song Y; Zhao Q; Yang Y; Zhang R
Pak J Pharm Sci; 2017 Mar; 30(2):551-553. PubMed ID: 28649083
[TBL] [Abstract][Full Text] [Related]
25. In vitro activity of fosfomycin combined with ceftazidime, imipenem, amikacin, and ciprofloxacin against Pseudomonas aeruginosa.
Tessier F; Quentin C
Eur J Clin Microbiol Infect Dis; 1997 Feb; 16(2):159-62. PubMed ID: 9105845
[TBL] [Abstract][Full Text] [Related]
26. In-vitro activities of various antibiotics, alone and in combination with amikacin against Pseudomonas aeruginosa.
Gerçeker AA; Gürler B
J Antimicrob Chemother; 1995 Oct; 36(4):707-11. PubMed ID: 8591946
[TBL] [Abstract][Full Text] [Related]
27. Comparative in vitro antimicrobial susceptibilities and synergistic activities of antimicrobial combinations against carbapenem-resistant Acinetobacter species: Acinetobacter baumannii versus Acinetobacter genospecies 3 and 13TU.
Sheng WH; Wang JT; Li SY; Lin YC; Cheng A; Chen YC; Chang SC
Diagn Microbiol Infect Dis; 2011 Jul; 70(3):380-6. PubMed ID: 21558048
[TBL] [Abstract][Full Text] [Related]
28. Antimicrobial activity of 12 broad-spectrum agents tested against 270 nosocomial blood stream infection isolates caused by non-enteric gram-negative bacilli: occurrence of resistance, molecular epidemiology, and screening for metallo-enzymes.
Jones RN; Pfaller MA; Marshall SA; Hollis RJ; Wilke WW
Diagn Microbiol Infect Dis; 1997 Nov; 29(3):187-92. PubMed ID: 9401811
[TBL] [Abstract][Full Text] [Related]
29. In vitro activity and synergy of bismuth thiols and tobramycin against Burkholderia cepacia complex.
Veloira WG; Domenico P; LiPuma JJ; Davis JM; Gurzenda E; Kazzaz JA
J Antimicrob Chemother; 2003 Dec; 52(6):915-9. PubMed ID: 14585856
[TBL] [Abstract][Full Text] [Related]
30. [Changes of antimicrobial resistance among nonfermenting gram-negative bacilli isolated from intensive care units from 1994 to 2001 in China].
Wang H; Chen MJ;
Zhonghua Yi Xue Za Zhi; 2003 Mar; 83(5):385-90. PubMed ID: 12820914
[TBL] [Abstract][Full Text] [Related]
31. Antibacterial properties of investigational, new, and commonly used antibiotics against isolates of Pseudomonas cepacia in Michigan.
Bhakta DR; Leader I; Jacobson R; Robinson-Dunn B; Honicky RE; Kumar A
Chemotherapy; 1992; 38(5):319-23. PubMed ID: 1283733
[TBL] [Abstract][Full Text] [Related]
32. Synergistic effect of combinations of sulfamethoxazole, trimethoprim, and colistin against Pseudomonas maltophilia and Pseudomonas cepacia.
Nord CE; Wadström T; Wretlind B
Antimicrob Agents Chemother; 1974 Oct; 6(4):521-3. PubMed ID: 4143759
[TBL] [Abstract][Full Text] [Related]
33. Susceptibility of multiresistant strains of Burkholderia cepacia to honey.
Cooper RA; Wigley P; Burton NF
Lett Appl Microbiol; 2000 Jul; 31(1):20-4. PubMed ID: 10886608
[TBL] [Abstract][Full Text] [Related]
34. Investigation of Burkholderia cepacia nosocomial outbreak with high fatality in patients suffering from diseases other than cystic fibrosis.
Shehabi AA; Abu-Al-Soud W; Mahafzah A; Khuri-Bulos N; Abu Khader I; Ouis IS; Wadström T
Scand J Infect Dis; 2004; 36(3):174-8. PubMed ID: 15119360
[TBL] [Abstract][Full Text] [Related]
35. Inducible amp C beta-lactamase producing gram-negative bacilli from blood stream infections: frequency, antimicrobial susceptibility, and molecular epidemiology in a national surveillance program (SCOPE).
Pfaller MA; Jones RN; Marshall SA; Coffman SL; Hollis RJ; Edmond MB; Wenzel RP
Diagn Microbiol Infect Dis; 1997 Aug; 28(4):211-9. PubMed ID: 9327251
[TBL] [Abstract][Full Text] [Related]
36. In vitro susceptibilities of Burkholderia mallei in comparison to those of other pathogenic Burkholderia spp.
Kenny DJ; Russell P; Rogers D; Eley SM; Titball RW
Antimicrob Agents Chemother; 1999 Nov; 43(11):2773-5. PubMed ID: 10543761
[TBL] [Abstract][Full Text] [Related]
37. Synergistic activities of macrolide antibiotics against Pseudomonas aeruginosa, Burkholderia cepacia, Stenotrophomonas maltophilia, and Alcaligenes xylosoxidans isolated from patients with cystic fibrosis.
Saiman L; Chen Y; Gabriel PS; Knirsch C
Antimicrob Agents Chemother; 2002 Apr; 46(4):1105-7. PubMed ID: 11897598
[TBL] [Abstract][Full Text] [Related]
38. In vitro synergistic effect of ciprofloxacin with aminoglycosides against multidrug resistant-Pseudomonas aeruginosa.
Yasmin F; Akhtar N; Hameed A
Pak J Pharm Sci; 2013 Sep; 26(5):1041-4. PubMed ID: 24035966
[TBL] [Abstract][Full Text] [Related]
39. In vitro activity of doripenem against Pseudomonas aeruginosa and Burkholderia cepacia isolates from both cystic fibrosis and non-cystic fibrosis patients.
Traczewski MM; Brown SD
Antimicrob Agents Chemother; 2006 Feb; 50(2):819-21. PubMed ID: 16436756
[TBL] [Abstract][Full Text] [Related]
40. Pseudomonas aeruginosa isolated from corneal ulcer: susceptibility to antimicrobial agents tested alone or in combination.
Hu FR; Luh KT
J Formos Med Assoc; 1992 Feb; 91(2):190-4. PubMed ID: 1364217
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
